Cahill D J, Fountain S A, Fox R, Fleming C F, Brinsden P R, Hull M G
University of Bristol Department of Obstetrics and Gynaecology, St. Michael's Hospital, Bristol, UK.
Hum Reprod. 1994 Jul;9(7):1243-6. doi: 10.1093/oxfordjournals.humrep.a138686.
All women undergoing pituitary down-regulation before planned in-vitro fertilization (IVF) treatment in two IVF units were studied to assess the risks of and to pregnancies occurring inadvertently when gonadotropin-releasing hormone agonists (GnRHa) were used to achieve pituitary desensitization during the luteal phase prior to planned IVF treatment. In 2670 cycles, 25 women conceived (0.9% of cycles). Of these, three resulted in pre-clinical abortions (12%) but there were no clinical abortions, and 22 have ended with live births at term of apparently normal infants. Collation of these and other published data suggest that pregnancy outcome is not adversely affected by GnRHa administration in the luteal phase of the conception cycle.
对两个体外受精（IVF）单位中所有计划进行体外受精治疗前接受垂体降调节的女性进行了研究，以评估在计划的体外受精治疗前的黄体期使用促性腺激素释放激素激动剂（GnRHa）实现垂体脱敏时意外怀孕的风险以及对妊娠的影响。在2670个周期中，有25名女性怀孕（占周期的0.9%）。其中，3例发生临床前流产（12%），但无临床流产，22例以足月产下明显正常的婴儿告终。对这些数据和其他已发表数据的整理表明，在受孕周期的黄体期给予GnRHa不会对妊娠结局产生不利影响。
